New York State Teachers Retirement System decreased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 3.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 310,394 shares of the biopharmaceutical company’s stock after selling 9,797 shares during the period. New York State Teachers Retirement System’s holdings in Alexion Pharmaceuticals were worth $40,655,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ALXN. Oakbrook Investments LLC bought a new stake in Alexion Pharmaceuticals in the 2nd quarter worth about $1,601,000. Fox Run Management L.L.C. bought a new stake in Alexion Pharmaceuticals in the 2nd quarter worth about $604,000. NEXT Financial Group Inc bought a new stake in Alexion Pharmaceuticals in the 2nd quarter worth about $36,000. We Are One Seven LLC grew its position in Alexion Pharmaceuticals by 5.7% in the 2nd quarter. We Are One Seven LLC now owns 1,586 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 86 shares in the last quarter. Finally, CWM Advisors LLC grew its position in Alexion Pharmaceuticals by 10.4% in the 2nd quarter. CWM Advisors LLC now owns 7,641 shares of the biopharmaceutical company’s stock worth $1,001,000 after purchasing an additional 719 shares in the last quarter. Institutional investors and hedge funds own 94.74% of the company’s stock.

A number of equities research analysts have issued reports on the stock. Citigroup downgraded shares of Barrick Gold to a “neutral” rating in a research report on Thursday, May 23rd. Wedbush set a $190.00 price objective on shares of Home Depot and gave the stock a “hold” rating in a research report on Wednesday, May 22nd. ValuEngine raised shares of Zuora from a “hold” rating to a “buy” rating in a research report on Saturday, July 6th. BidaskClub downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 9th. Finally, Raymond James upped their price objective on shares of Spotify Technology from $172.00 to $180.00 and gave the stock a “strong-buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $162.27.

Alexion Pharmaceuticals stock opened at $111.11 on Monday. Alexion Pharmaceuticals, Inc. has a twelve month low of $92.56 and a twelve month high of $141.86. The company’s 50 day moving average is $124.13. The company has a market cap of $25.70 billion, a P/E ratio of 15.67, a P/E/G ratio of 1.12 and a beta of 1.64. The company has a quick ratio of 3.56, a current ratio of 4.04 and a debt-to-equity ratio of 0.26.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.51. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The firm had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the prior year, the firm earned $2.07 EPS. The company’s revenue was up 15.1% compared to the same quarter last year. As a group, research analysts expect that Alexion Pharmaceuticals, Inc. will post 8.81 earnings per share for the current fiscal year.

In other news, EVP Indrani Lall Franchini sold 4,500 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $132.78, for a total transaction of $597,510.00. Following the completion of the transaction, the executive vice president now directly owns 29,627 shares of the company’s stock, valued at approximately $3,933,873.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bros. Advisors Lp Baker sold 300,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $123.74, for a total transaction of $37,122,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 428,567 shares of company stock valued at $53,420,869 over the last three months. Insiders own 4.08% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Article: What is a stock portfolio tracker?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.